Sino Biopharmaceutical Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SBMFF | GMAB | LGND | EXEL | ROIV | BNTX | |
|---|---|---|---|---|---|---|
| Market cap | 12.37B | 23.50B | 5.89B | 15.48B | 24.56B | 22.03B |
| P/E (TTM) | 34.8 | 30.1 | 31.1 | 19.7 | — | — |
| Forward P/E | — | 25.2 | 24.7 | 14.6 | -19.8 | -15.6 |
| Price/book | 2.5 | 3.8 | 6.1 | 8.4 | 5.8 | 1.1 |
| Dividend yield | 2.20% | — | — | — | — | — |
| 1-year change | −23.63% | +21.15% | +58.26% | +80.17% | +89.01% | −18.75% |
| Today | 0.00% | +3.28% | −0.99% | +0.42% | +1.40% | −2.76% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SBMFF news ›STADA and Sino Biopharmaceutical Enter into Exclusive Partnership for up to Four Biosimilars, Including to MSD’s Keytruda® (Pembrolizumab)
Home / News / BioBlast® On 28 September 2026, STADA announced that it has entered into an exclusive partnership with Chia Tai Tianqing Pharmaceutical Group (CTTQ), a subsidiary of Sino Biopharmaceutical Limited, for up to four biosimilars.…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
pearceip.law1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.